Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20164676
Chung SH, et al. (2010) A double point mutation in PCL-gamma1 (Y509A/F510A) enhances Y783 phosphorylation and inositol phospholipid-hydrolyzing activity upon EGF stimulation. Exp Mol Med 42, 216-27 20164676
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y509-p - PLCG1 (rat)
Modsite: NHEWyPHyFVLTSSK SwissProt Entrez-Gene
Orthologous residues
PLCG1 (human): Y509‑p, PLCG1 iso2 (human): Y509‑p, PLCG1 (mouse): Y509‑p, PLCG1 (rat): Y509‑p, PLCG1 (cow): Y509‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Relevant cell lines - cell types - tissues:  COS (fibroblast)
Cellular systems studied:  cell lines
Species studied:  green monkey
Downstream Regulation
Effect of modification (function):  enzymatic activity, inhibited, phosphorylation
Comments:  Y509A/F510A mutant PLCG1 has enhanced phosphorylation of Y783, but no longer requires Y783 phosphorylation for enzymatic activation

Y771-p - PLCG1 (rat)
Modsite: IGTAEPDyGALyEGR SwissProt Entrez-Gene
Orthologous residues
PLCG1 (human): Y771‑p, PLCG1 iso2 (human): Y771‑p, PLCG1 (mouse): Y771‑p, PLCG1 (rat): Y771‑p, PLCG1 (cow): Y771‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  COS (fibroblast)
Cellular systems studied:  cell lines
Species studied:  green monkey
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF no change compared to control wild-type or Y509A/F510A mutant PLCG1

Y783-p - PLCG1 (rat)
Modsite: EGRNPGFyVEANPMP SwissProt Entrez-Gene
Orthologous residues
PLCG1 (human): Y783‑p, PLCG1 iso2 (human): Y783‑p, PLCG1 (mouse): Y783‑p, PLCG1 (rat): Y783‑p, PLCG1 (cow): Y783‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  COS (fibroblast)
Cellular systems studied:  cell lines
Species studied:  green monkey
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase enhanced EGF-induced increase in Y509A/F510A mutant PLCG1
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

Y1253-p - PLCG1 (rat)
Modsite: EGsFEARyQQPFEDF SwissProt Entrez-Gene
Orthologous residues
PLCG1 (human): Y1253‑p, PLCG1 iso2 (human): Y1254‑p, PLCG1 (mouse): Y1253‑p, PLCG1 (rat): Y1253‑p, PLCG1 (cow): Y1254‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  COS (fibroblast)
Cellular systems studied:  cell lines
Species studied:  green monkey
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase enhanced EGF-induced increase in Y509A/F510A mutant PLCG1